Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1992-07-31
1995-07-25
Lacey, David L.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303884, 5303893, 5303895, 435 702, C07K 1612, C07K 1600, C12N 1512
Patent
active
054363217
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF THE INVENTION
The present invention relates to newly discovered and isolated proteins and to methods and compositions including such proteins for preventing or treating sepsis. More particularly, the present invention relates to a molecule that binds to lipopolysaccharide (LPS) and to the CD14 monocyte differentiation antigen, and to antibodies thereto that may thereby inhibit the binding of LPS complexes by CD14-expressing cells.
BACKGROUND OF THE INVENTION
Sepsis is morbid condition induced by a toxin, the introduction or accumulation of which is most commonly caused by infection or trauma. The initial symptoms of sepsis typically include chills, profuse sweat, irregularly remittent fever, prostration and the like, followed by persistent fever, hypotension leading to shock, neutropenia, leukopenia, disseminated intravascular coagulation, adult respiratory distress syndrome and multiple organ failure.
Sepsis-inducing toxins have been found associated with pathogenic bacteria, viruses, plants and venoms. Among the well described bacterial toxins are the endotoxins or lipopolysaccharides(LPS) of the gram-negative bacteria. These molecules are glycolipids that are ubiquitous in the outer membrane of all gram-negative bacteria. While the chemical structure of most of the LPS molecule is complex and diverse, a common feature is the lipid A region of LPS [E. Th. Rietschel et al., in Handbook of Endotoxins, 1:187-214 eds., R. A. Proctor and E. Th. Rietschel, Elsevier, Amsterdam (1984)]; recognition of lipid A in biologic systems initiates many, if not all, of the pathophysiologic changes of sepsis. Because lipid A structure is highly conserved among all types of gram-negative organisms, common pathophysiologic changes characterize gram-negative sepsis.
LPS is believed to be a primary cause of death in humans during gram-negative sepsis, particularly when the symptoms include adult respiratory distress syndrome (ARDS) [van Deventer et al., Lancet, 1:605 (1988); ziegler et al., J. Infect. Dis., 136:19-28 (1987)]. For instance, one particular cytokine, tumor necrosis factor alpha/cachectin (TNF), has recently been reported to be a primary mediator of septic shock [Beutler et al., N. Eng. J. Med., 316:379 (1987)]. Intravenous injection of LPS endotoxin from bacteria into experimental animals and man produces a rapid, transient release of TNF [Beutler et al., J. Immunol., 135:3972 (1985); Mathison et al., J. Clin. Invest. 81:1925 (1988)]. Evidence that TNF is a critical mediator of septic shock comes primarily from experiments in which pretreatment of animals with anti-TNF antibodies reduces lethality [Beutler et al., Science, 229:869, (1985); Mathison et al., J. Clin. Invest, 81:1925 (1988)]. These reports suggest that interruption of the secretion of TNF caused by LPS or other factors would ameliorate the often lethal symptoms of sepsis.
Current concepts support the contention that the primary response of the host to LPS (including man) involves the recognition of LPS by cells of the monocyte/macrophage lineage, followed by the rapid elaboration of a variety of cell products including the general group known as cytokines. Other cell types believed to participate in sepsis and in particular in the response to LPS are polymorphonuclear leukocytes (PMN) and endothelial cells; each of these cell types are also capable of responding to LPS with the elaboration of potent inflammatory substances, and in the case of polymorphonuclear leukocytes, the elaboration of cytotoxic molecules.
Upon introduction of LPS into the blood, it may bind to a protein termed lipopolysaccharide binding protein (LBP). LBP is a 60 kD glycoprotein present at concentrations of less than 100 ng/ml in the serum of healthy animals and man. During the acute phase, LBP is synthesized by hepatocytes, and reaches concentrations of 30-50 ug/ml in serum. LBP can be purified from acute phase human and rabbit serum [Tobias et al. J. Exp. Med., 164:777-793 (1986)]. LBP recognizes the lipid A region of LPS and forms high affinity, 1:1 s
REFERENCES:
patent: 4315906 (1982-02-01), Gelder
Stone, R., Science, 259:1243, 26 Feb. 1993.
Rhein, R., Biotechnology Newswatch, pp. 1 and 3, Oct. 4, 1993.
Waldmann, T. A., Science, 252: 1657-1662, Jun. 1991.
Harris, W. J. et al, Tibtech, 11: 42-44, Feb. 1993.
Kirikae, et al. Microbiol. Immunol., 32 (1), pp. 33-44, (1988).
Lo et al., J. Exp. Med., 169, pp. 1779-1793 (1989).
Lo et al., J. Immunol., 143 pp. 3325-3329 (1989).
Roeder et al., Infect. and Immunity, 57, pp. 1054-1058 (1989).
Springer et al., Biochem., 13, pp. 1379-1389 (1974).
Wright, et al., J. Exp. Med., 170, pp. 1231-1241 (1989).
Wright et al., J. Immunol. 136, pp. 1759-1764 (1986).
Lacey David L.
Loring Susan
The Rockefeller University
LandOfFree
Antibodies to the lipopolysaccharide bonding opsonin septin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to the lipopolysaccharide bonding opsonin septin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to the lipopolysaccharide bonding opsonin septin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-740345